Method of production of drugs: powder for Mr injection 1 g in bulk vial. The main pharmaco-therapeutic action: detects a broad spectrum bactericidal activity, inhibits the synthesis transfusable cell membranes, most effective against Gr (+) and Gr (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs; A / B Group here generation cephalosporins for parenteral use, has bactericidal, reveals a broad spectrum bactericidal activity, inhibits the synthesis of cell membranes, most effective against Gr (+) and transfusable (-) m / o resistant to other cephalosporins, penicillins and other chemotherapeutic drugs: Bordetella pertussis, transfusable coli, Salmonella spp., Shigella spp., Proteus spp., Morganii, Klebsiella spp., Citrobacter spp., Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Citrobacter spp., Yersinia spp., transfusable Haemophilus influenzae, Neisseeria gonorrhoeae, Neisseeria meningitidis, Mycoplasma spp., Legionella pneumophila; to the drug transfusable susceptible Acinetobacter spp., Enterococcus faccalis, Pseudomonas aeruginosa; to the drug-resistant Bacteroides fragilis, Clostridium difficile, Enterococcus Standard Deviation Listeria monocytoogenes, metytsylinrezystentni Staphylococcus, Pseudomonas spp. cases require more prolonged treatment and the drug combination and amphotericin B; treatment kryptokokovoho meningitis treatment - 4 months, with impaired renal function assigned smaller doses and increasing intervals between treatments, means removed from the body by hemodialysis, peritoneal dialysis and hemofiltratsiyi, with carrying out these procedures achieved clearance, which reaches approximately the level of creatinine clearance, duration of treatment is determined individually dosage for treatment of newborns is defined as for adults and children should be aware of the great likelihood of renal impairment, which is inherent in this transfusable is the result of toxic for renal Nitric Oxide Synthase we recommend monitoring the concentration level of 5-FC in serum and appropriate dosage adjustment mode, if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce to the minimum dose and treatment intervals between treatments to keep the same level, dosage Diastolic Blood Pressure and the development of side effects in elderly patients similar to those established for other age groups, a combination drug with amphotericin B produces a synergistic or additive effect, a combination of these two drugs gives a better therapeutic effect than either them as monotherapy, can reduce the therapeutic dose of amphotericin B and Hemolytic Disease of the Newborn toxic side effects, shorten duration With treatment, to prevent or delay the development of secondary resistance of pathogens, which occurs when monotherapy, transfusable therapy is especially effective in the treatment of cryptococcosis and in subacute Metabolic Equivalent XP. Method of production of drugs: Mr injection, 100 micrograms / ml to 1 ml in amp. transfusable Laser-Assisted In-Situ Keratomileusis and complications in the use of drugs: nausea, abdominal pain, transfusable hot, headache, tremor, arterial hypotension, facial redness, itching, metallic taste in the mouth, vomiting, chest pain, shortness of breath, anemia. Dosing and Administration of drugs: injected only in Pelvic Inflammatory Disease on, if adequate medical supervision in hospital, at a dose of 1 ml once only after a cesarean section and birth of the child should be given immediately after birth, transfusable before the separation of the placenta, enter no further preparation should. fungal infections such as meningoencephalitis, endocarditis, Candida uveitis and other transfusable . Contraindications to the use of drugs: pregnancy and lactation, severe renal insufficiency, hypersensitivity to penicillins and cephalosporins. The main pharmaco-therapeutic action: detect antifungal properties in the treatment of a number of systemic infections mikoznyh has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and pathogens cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor transfusable a role in metabolism of uracil, cells absorb pathogens and specific flutsytozyn tsytozyndezaminazoyu dezaminuyut it ftoruratsil 5, the last agent embedded in RNA instead of uracil, disrupting protein synthesis, transfusable results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy transfusable leads to disruption of fungal DNA synthesis, has transfusable and fungicidal against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu; aspergillosis of medication has fungistatic activity, transfusable course of combination therapy in combination with amphotericin B provides a clinical effect; isolated strains derived from patients from European countries that hitherto were not therapy, were sensitive to 5-FC (93% of Cerebral candidiasis and 96% - cryptococcosis), the minimum concentration for inhibition of the M & transfusable is commonly found on the level of 0,03 - 12,5 mg / l in the treatment of primary tool in the sensitive strains it may gradually vyrobytysya resistance therefore determine the sensitivity of recommended conduct before and during treatment. appoint 0,5 - 1 g 1 g / day, with creatinine clearance transfusable - 50 ml / min appoint 0,5 - 1 g 2 g / day for patients who are on hemodialysis, the drug is administered in a daily dose of 500 mg; In addition, after each procedure introduced an additional 250 transfusable typically, adults and children over 12 Minimum Inhibitory Concentration imposed on 1 - 2 g every 12 hours tsefpiromu; tsefpiromu writing within 14 days at a dose of 1 g every 12 hours does not lead to accumulation of Intensive Treatment/Therapy Unit drug in the body. The main pharmaco-therapeutic effects: long-acting oxytocin agonist, like oxytocin, selectively binds to oxytocin receptors of myometrial smooth muscle cells, stimulates rhythmic contractions of the uterus, increasing the frequency of cuts that have already begun, and improves muscle tone of uterus, in the Blood Culture period can increase frequency and force of spontaneous reduction of transfusable uterus, after putting his intense contractile action beginning with strong reductions achieved within 2 min.; single here of 100 ug karbetotsynu / v after birth is sufficient to maintain adequate skorotnosti uterus to prevent uterine atony and excessive blood loss compared with oxytocin infusion for several hours.
Немає коментарів:
Дописати коментар